IGF1 and colorectal carcinoma: Common mutations in genes encoding downstream members of the insulin/IGF pathway, such as KRAS and BRAF, are known predictors of the biological potential of CRC and also dictate a response to treatment relying on IR/IGF1R inhibitors [119].